thalidomide has been researched along with Rhabdomyolysis in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Rhabdomyolysis: Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shahan, JL | 1 |
| Panu, LD | 1 |
| Hildebrandt, GC | 1 |
| Boga, C | 1 |
| Ozdogu, H | 1 |
| Yeral, M | 1 |
| Kizilkilic, E | 1 |
| Tamer, L | 1 |
2 other studies available for thalidomide and Rhabdomyolysis
| Article | Year |
|---|---|
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combi | 2012 |
Thalidomide in combination with dexamethasone-induced rhabdomyolysis in a patient with refractory myeloma.
Topics: Antineoplastic Agents, Hormonal; Dexamethasone; Drug Therapy, Combination; Humans; Immunoglobulin A; | 2007 |